Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tibulizumab in Adults With Systemic Sclerosis
NCT06843239Phase 2Active, not recruiting
- Sponsor
- Zura Bio
- Start
- Feb 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Tibulizumab with Placebo (2 arms). Primary endpoints: modified Rodnan Skin Score at 24 weeks and Safety and tolerability at 52 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
tibulizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06843239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843239.